Related Experiment Video
Updated: Aug 15, 2025
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
In Silico Identification and In Vitro Evaluation of New ABCG2 Transporter Inhibitors as Potential Anticancer Agents
Simone Di Micco1, Veronica Di Sarno2, Martina Rossi3,4
1European Biomedical Research Institute of Salerno, Via S. De Renzi 50, 84125 Salerno, Italy.
Abstract:
Different molecular mechanisms contribute to the development of multidrug resistance in cancer, including increased drug efflux, enhanced cellular repair mechanisms and alterations of drug metabolism or drug targets. ABCG2 is a member of the ATP-binding cassette superfamily transporters that promotes drug efflux, inducing chemotherapeutic resistance in malignant cells. In this context, the development of selective ABCG2 inhibitors might be a suitable strategy to improve chemotherapy efficacy. Thus, through a multidisciplinary approach, we identified a new ABCG2 selective inhibitor (8), highlighting its ability to increase mitoxantrone cytotoxicity in both hepatocellular carcinoma (ECfrom 8.67 ± 2.65 to 1.25 ± 0.80 μM) and transfected breast cancer cell lines (ECfrom 9.92 ± 2.32 to 2.45 ± 1.40 μM). Moreover, mitoxantrone co-administration in both transfected and non-transfected HEK293 revealed that compound 8 notably lowered the mitoxantrone EC50, demonstrating its efficacy along with the importance of the ABCG2 extrusion pump overexpression in MDR reversion. These results were corroborated by evaluating the effect of inhibitor 8 on mitoxantrone cell uptake in multicellular tumor spheroids and via proteomic experiments.
Insights
Researchers identified a novel ABCG2 inhibitor (compound 8) that enhances chemotherapy efficacy. This compound effectively reverses multidrug resistance (MDR) by increasing the cytotoxicity of mitoxantrone in cancer cells.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Multidrug resistance (MDR) in cancer involves mechanisms like increased drug efflux.
- ABCG2, an ATP-binding cassette transporter, promotes drug efflux and contributes to MDR.
- Targeting ABCG2 offers a potential strategy to overcome chemotherapy resistance.
Purpose of the Study:
- To identify and characterize a novel selective inhibitor of ABCG2.
- To evaluate the efficacy of the identified inhibitor in reversing ABCG2-mediated multidrug resistance.
- To assess the compound's impact on the cytotoxicity of chemotherapeutic agents.
Main Methods:
- Multidisciplinary approach to identify a selective ABCG2 inhibitor (compound 8).
- Assay of mitoxantrone cytotoxicity in hepatocellular carcinoma and breast cancer cell lines.
- Evaluation of compound 8's effect on mitoxantrone EC50 in HEK293 cells (transfected and non-transfected).
- Assessment of mitoxantrone cell uptake in multicellular tumor spheroids and proteomic analysis.
Main Results:
- Compound 8 selectively inhibits ABCG2.
- It significantly increased mitoxantrone cytotoxicity in hepatocellular carcinoma and breast cancer cells.
- Compound 8 reduced mitoxantrone EC50, confirming ABCG2's role in MDR and demonstrating the inhibitor's efficacy.
- Inhibitor 8 enhanced mitoxantrone uptake in tumor spheroids.
Conclusions:
- A novel selective ABCG2 inhibitor (compound 8) was identified.
- Compound 8 effectively reverses ABCG2-mediated multidrug resistance, enhancing chemotherapy efficacy.
- This inhibitor shows promise for improving cancer treatment strategies by overcoming drug resistance.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:31ABC Transporters: Exporter